Success Metrics

Clinical Success Rate
58.5%

Based on 31 completed trials

Completion Rate
58%(31/53)
Active Trials
76(40%)
Results Posted
90%(28 trials)
Terminated
22(12%)

Phase Distribution

Ph phase_1
30
16%
Ph not_applicable
51
27%
Ph phase_2
87
46%
Ph phase_3
9
5%

Phase Distribution

30

Early Stage

87

Mid Stage

9

Late Stage

Phase Distribution177 total trials
Phase 1Safety & dosage
30(16.9%)
Phase 2Efficacy & side effects
87(49.2%)
Phase 3Large-scale testing
9(5.1%)
N/ANon-phased studies
51(28.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

53.4%

31 of 58 finished

Non-Completion Rate

46.6%

27 ended early

Currently Active

76

trials recruiting

Total Trials

188

all time

Status Distribution
Active(96)
Completed(31)
Terminated(27)
Other(34)

Detailed Status

Recruiting51
unknown34
Completed31
Active, not recruiting25
Terminated22
Not yet recruiting20

Development Timeline

Analytics

Development Status

Total Trials
188
Active
76
Success Rate
58.5%
Most Advanced
Phase 3

Trials by Phase

Phase 130 (16.9%)
Phase 287 (49.2%)
Phase 39 (5.1%)
N/A51 (28.8%)

Trials by Status

not_yet_recruiting2011%
recruiting5127%
terminated2212%
withdrawn53%
completed3116%
unknown3418%
active_not_recruiting2513%

Recent Activity

Clinical Trials (188)

Showing 20 of 188 trialsScroll for more
NCT03141359Phase 2

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Active Not Recruiting
NCT02306954Phase 2

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Active Not Recruiting
NCT07721181Not Applicable

Radiotherapy Dose Escalation for Non-operative Management of Unresectable Locally Recurrent Rectal Cancer (STEP-UP)

Recruiting
NCT07717268Phase 2

Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

Recruiting
NCT06686771Phase 3

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Recruiting
NCT05990192Phase 2

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Recruiting
NCT04302025Phase 2

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Recruiting
NCT04619069Phase 1

Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

Active Not Recruiting
NCT04020276Not Applicable

OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases

Recruiting
NCT06825091Phase 3

Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)

Recruiting
NCT04070209Phase 2

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

Active Not Recruiting
NCT06437977Phase 3

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)

Recruiting
NCT07579598Phase 2

ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma

Not Yet Recruiting
NCT06323239Phase 2

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Recruiting
NCT04996914Not Applicable

Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma

Recruiting
NCT06523894Not Applicable

Ablative SBRT in Elderly BC Patients

Recruiting
NCT05524168Phase 2

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Active Not Recruiting
NCT06800339Phase 1

A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer

Recruiting
NCT05138900Not Applicable

A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer

Active Not Recruiting
NCT07413523Not Applicable

Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy in Patients Affected by Oligometastatic uRothelial carcinomA

Recruiting

Drug Details

Intervention Type
RADIATION
Total Trials
188